GlassScriptPhysician profile
Douglas G Briggs
NPI 1851697965
$2,643.22
in general payments reported to CMS, 2019-2025
29 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $125 · 2021: $664 · 2022: $422 · 2023: $339 · 2024: $461 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $253.32 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $190.17 | 2022-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.57 | 2020-2025 | Jardiance |
| Gilead Sciences, INC. | $178.73 | 2022-2025 | Epclusa |
| Merck Sharp & Dohme LLC | $120.86 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Glaxosmithkline, LLC. | $98.54 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $66.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $64.72 | 2020-2021 | |
| Pfizer INC. | $55.19 | 2023-2024 | |
| Biogen, INC. | $54.84 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.18 | 2022-2025 | Caplyta |
| Viiv Healthcare Company | $42.56 | 2025 | Apretude |
| Organon LLC | $42.47 | 2024-2025 | Nexplanon |
| Exact Sciences Corporation | $38.09 | 2023 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $33.26 | 2021 | |
| Amgen INC. | $30.59 | 2024 | Otezla, Repatha |
| Abbott Laboratories | $29.77 | 2024 | Eterna |
| Seqirus USA INC | $24.60 | 2024 | Flucelvax, Fluad |
| Radius Health, INC. | $23.35 | 2019 | |
| Insulet Corporation | $21.35 | 2021 | |
| Medtronic, INC. | $17.86 | 2023 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $17.12 | 2021 | |
| Agile Therapeutics, INC. | $16.75 | 2021 | |
| Dexcom, INC. | $15.72 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $15.21 | 2022 | |
| Exeltis, USA INC. | $14.14 | 2024 | Slynd |
| Phadia US INC. | $13.68 | 2025 | Immunocap |
| Irhythm Technologies, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.